Spotlight on Scientific Discovery & Engineering: Cancer Complexity and Cellular Innovation

This JOSHA Spotlight curates five advances that illuminate cancer as a problem of both cellular engineering and clinical decision-making. Mechanistic work in colorectal cancer shows how loss of ATRX disrupts colonic identity, unleashing multilineage plasticity and highly metastatic behaviour. A microfluidic–machine learning platform in breast cancer quantifies how metronomic drug schedules can outperform conventional combinations. A landmark trial in node-positive breast cancer refines care by safely omitting regional nodal irradiation after excellent chemotherapy response. In pancreatic cancer, paired articles reveal “cryptic” antigens from noncoding regions as shared, tumour-restricted targets that can be recognised and attacked by engineered T cells, yet remain constrained by an immunosuppressive microenvironment. Together, these curated contributions spanning cellular identity in colorectal cancer, dosing logic in breast cancer, and immune recognition in pancreatic cancer showcase how tightly linked molecular identity, dosing logic, and immune recognition are reshaping the future of precision oncology and patient care.